Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

G. Norman; S. Rice; E. Spackman; L. Stirk; A. Danso-Appiah; D. Suh; S. Palmer; A. Eastwood

doi:10.3310/hta15suppl1/04

Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

G. Norman, S. Rice, E. Spackman, L. Stirk, A. Danso-Appiah, D. Suh, S. Palmer, A. Eastwood

Human Factors & Behavioral Neurobiology

University of York

Research output: Contribution to journal › Review article › peer-review

Original language	English
Pages (from-to)	33-42
Number of pages	10
Journal	Health Technology Assessment
Volume	15 Suppl 1
DOIs	https://doi.org/10.3310/hta15suppl1/04
State	Published - May 2011

ASJC Scopus Subject Areas

Health Policy

Access to Document

10.3310/hta15suppl1/04

Cite this

@article{b1f892dcd2374a3e993c3e288e76e2ca,

title = "Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.",

author = "G. Norman and S. Rice and E. Spackman and L. Stirk and A. Danso-Appiah and D. Suh and S. Palmer and A. Eastwood",

year = "2011",

month = may,

doi = "10.3310/hta15suppl1/04",

language = "English",

volume = "15 Suppl 1",

pages = "33--42",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "National Coordinating Centre for Health Technology Assessment",

}

TY - JOUR

T1 - Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

AU - Norman, G.

AU - Rice, S.

AU - Spackman, E.

AU - Stirk, L.

AU - Danso-Appiah, A.

AU - Suh, D.

AU - Palmer, S.

AU - Eastwood, A.

PY - 2011/5

Y1 - 2011/5

UR - https://www.scopus.com/pages/publications/84891723797

UR - https://www.scopus.com/inward/citedby.url?scp=84891723797&partnerID=8YFLogxK

U2 - 10.3310/hta15suppl1/04

DO - 10.3310/hta15suppl1/04

M3 - Review article

C2 - 21609651

AN - SCOPUS:84891723797

SN - 1366-5278

VL - 15 Suppl 1

SP - 33

EP - 42

JO - Health Technology Assessment

JF - Health Technology Assessment

ER -

Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this